AAAAAA
Results:
1-25
|
Results: 25
Authors:
Nathan, RA
Kemp, JP
Citation: Ra. Nathan et Jp. Kemp, Efficacy of antileukotriene agents in asthma management, ANN ALLER A, 86(6), 2001, pp. 9-17
Authors:
Bousquet, J
Ait-Khaled, N
Annesi-Maesano, I
Baena-Cagnani, C
Bateman, E
Bonini, S
Canonica, GW
Carlsen, KH
Demoly, P
Durham, SR
Enarson, D
Fokkens, WJ
van Wijk, RG
Howarth, P
Ivanova, NA
Kemp, JP
Klossek, JM
Lockey, RF
Lund, V
Mackay, I
Malling, HJ
Meltzer, EO
Mygind, N
Okunda, M
Pawankar, R
Price, D
Scadding, GK
Simons, FER
Szczeklik, A
Valovirta, E
Vignola, AM
Wang, DY
Warner, JO
Weiss, KB
Citation: J. Bousquet et al., Recommendations, J ALLERG CL, 108(5), 2001, pp. S147-S334
Authors:
Kemp, JP
Kemp, JA
Citation: Jp. Kemp et Ja. Kemp, Management of asthma in Children, AM FAM PHYS, 63(7), 2001, pp. 1341
Authors:
Kemp, JP
Citation: Jp. Kemp, Role of leukotriene receptor antagonists in pediatric asthma, PEDIAT PULM, 30(2), 2000, pp. 177-182
Authors:
Kemp, JP
Hansmann, UHE
Chen, ZY
Citation: Jp. Kemp et al., Is there a universality of the helix-coil transition in protein models?, EUR PHY J B, 15(2), 2000, pp. 371-374
Authors:
Korenblat, PE
Kemp, JP
Scherger, JE
Minkwitz, MC
Mezzanotte, W
Citation: Pe. Korenblat et al., Effect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT), ANN ALLER A, 84(2), 2000, pp. 217-225
Authors:
Glaser, V
Kemp, JP
Citation: V. Glaser et Jp. Kemp, In my opinion - Interview with the expert, PED ASTHMA, 14(2), 2000, pp. 145-148
Authors:
Kemp, JP
Berkowitz, RB
Miller, SD
Murray, JJ
Nolop, K
Harrison, JE
Citation: Jp. Kemp et al., Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma, J ALLERG CL, 106(3), 2000, pp. 485-492
Authors:
Kemp, JP
Citation: Jp. Kemp, Guidelines update - Where do the new therapies fit in the management of asthma?, DRUGS, 59, 2000, pp. 23-28
Authors:
Valacer,"Witzmann, K
Fink, R
Helms, PJ
Kemp, JP
Becker, A
Price, D
Citation: K. Valacer,"witzmann et al., Questions and answers, DRUGS, 59, 2000, pp. 43-45
Authors:
Edelman, JM
Turpin, JA
Bronsky, EA
Grossman, J
Kemp, JP
Ghannam, AF
DeLucca, PT
Gormley, GJ
Pearlman, DS
Citation: Jm. Edelman et al., Oral Montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction - A randomized, double-blind trial, ANN INT MED, 132(2), 2000, pp. 97-104
Authors:
Kemp, JP
Skoner, DP
Szefler, SJ
Walton-Bowen, K
Cruz-Rivera, M
Smith, JA
Citation: Jp. Kemp et al., Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children, ANN ALLER A, 83(3), 1999, pp. 231-239
Authors:
Kemp, JP
Chen, ZY
Citation: Jp. Kemp et Zy. Chen, Semianalytical calculation of the Rouse dynamics of randomly branched polymers, PHYS REV E, 60(3), 1999, pp. 2994-2998
Authors:
Bernstein, DI
Berkowitz, RB
Chervinsky, P
Dvorin, DJ
Finn, A
Gross, GN
Karetzky, M
Kemp, JP
Laforce, C
Lumry, W
Mendelson, LM
Nelson, H
Pearlman, D
Rachelefsky, G
Ratner, P
Repsher, L
Segal, AT
Selner, JC
Settipane, GA
Wanderer, A
Cuss, FM
Nolop, KB
Harrison, JE
Citation: Di. Bernstein et al., Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler, RESP MED, 93(9), 1999, pp. 603-612
Authors:
Wasserman, SI
Kemp, JP
Rachelefsky, GS
Fireman, P
Shapiro, GG
Busse, WW
Citation: Si. Wasserman et al., Inhaled corticosteroids and likelihood of cataract extraction, J AM MED A, 281(9), 1999, pp. 791-792
Authors:
Kemp, JP
Korenblat, PE
Scherger, JE
Minkwitz, M
Citation: Jp. Kemp et al., Zafirlukast in clinical practice - Results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) in patients with asthma, J FAM PRACT, 48(6), 1999, pp. 425-432
Authors:
Kemp, JP
DeGraff, AC
Pearlman, DS
Wang, YH
Arledge, TE
Welch, MB
O'Riordan, TG
Herrle, MR
Stahl, EG
Citation: Jp. Kemp et al., A 1-year study of salmeterol powder on pulmonary function and hyperresponsiveness to methacholine, J ALLERG CL, 104(6), 1999, pp. 1189-1197
Authors:
Kemp, JP
Citation: Jp. Kemp, Study designs and challenges in clinical studies conducted in infants and children with asthma, J ALLERG CL, 104(4), 1999, pp. S184-S190
Authors:
McFadden, ER
Casale, TB
Edwards, TB
Kemp, JP
Metzger, J
Nelson, HS
Storms, WW
Neidl, MJ
Citation: Er. Mcfadden et al., Administration of budesonide once daily by means of Turbuhaler to subjectswith stable asthma, J ALLERG CL, 104(1), 1999, pp. 46-52
Authors:
Rosenthal, RR
Busse, WW
Kemp, JP
Baker, JW
Kalberg, C
Emmett, A
Rickard, KA
Citation: Rr. Rosenthal et al., Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness, CHEST, 116(3), 1999, pp. 595-602
Authors:
Nelson, H
Kemp, JP
Bieler, S
Vaughan, LM
Hill, MR
Citation: H. Nelson et al., Comparative efficacy and safety of albuterol sulfate spiros inhaler and albuterol metered-dose inhaler in asthma, CHEST, 115(2), 1999, pp. 329-335
Authors:
Kemp, JP
Minkwitz, MC
Bonuccelli, CM
Warren, MS
Citation: Jp. Kemp et al., Therapeutic effect of zafirlukast as monotherapy in steroid-naive patientswith severe persistent asthma, CHEST, 115(2), 1999, pp. 336-342
Authors:
Kemp, JP
Citation: Jp. Kemp, Comprehensive asthma management: Guidelines for clinicians, J ASTHMA, 35(8), 1998, pp. 601-620
Authors:
Nathan, RA
Bernstein, JA
Bielory, L
Bonuccelli, CM
Calhoun, WJ
Galant, SP
Hanby, LA
Kemp, JP
Kylstra, JW
Nayak, AS
O'Connor, JP
Schwartz, HJ
Southern, DL
Spector, SL
Williams, PV
Citation: Ra. Nathan et al., Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction, J ALLERG CL, 102(6), 1998, pp. 935-942
Authors:
Wong, SL
Kearns, GL
Kemp, JP
Drajesk, J
Chang, M
Locke, CS
Dube, LM
Awni, WM
Citation: Sl. Wong et al., Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma, EUR J CL PH, 54(9-10), 1998, pp. 715-719
Risultati:
1-25
|